JWA
LCTX icon

JFS Wealth Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

JFS Wealth Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3
Closed – – 557
2020
Q1 		$0 Hold
3
– – ﹤0.01% 538
2019
Q4 		$0 Buy
+3
New +$2 ﹤0.01% 534

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JFS Wealth Advisors's LCTX Position: Q2 2020 in Review

JFS Wealth Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q2 2020, closing a stake of 3 shares.

JFS Wealth Advisors first reported a position in LCTX in Q4 2019 and held it in 2 quarters. The position peaked at $0 in Q1 2020. 94 funds tracked by Wall St. Rank hold LCTX as of Q2 2020.

  • JFS Wealth Advisors reported no remaining Lineage Cell Therapeutics position as of Q2 2020 after selling out during the quarter.
  • JFS Wealth Advisors sold 3 Lineage Cell Therapeutics shares in Q2 2020.
  • JFS Wealth Advisors first reported a position in Lineage Cell Therapeutics in Q4 2019 and held it in 2 quarters.
  • JFS Wealth Advisors's Lineage Cell Therapeutics position peaked at $0 in Q1 2020.
  • 94 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2020.

Based on JFS Wealth Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.